ZLTQ Zeltiq Aesthetics, Inc.

2012 Stock Plan

2011 Equity Incentive Plan

2011 Employee Stock Purchase Plan

2005 Stock Incentive Plan

(Full Title of the Plans)

A. Robert D. Bailey

Chief Legal Officer and Corporate Secretary

Allergan plc

Morris Corporate Center III

400 Interpace Parkway

Parsippany, New Jersey 07054

(Name and address of agent for service)

Telephone number, including area code, of agent for service:

(862) 261-7000

Copy to:

Andrew L. Bab

Debevoise & Plimpton LLP

919 Third Avenue

New York, NY 10022

(212) 909-6323

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨  ☐

DEREGISTRATION OF SECURITIES

ZELTIQ Aesthetics, Inc., an Delaware corporation (the “ Company ”) is filing these Post-Effective Amendments to each of the following Registration Statements on Form S-8 (collectively, the “ Registration Statements ”) to deregister any and all securities that remain unsold under such Registration Statements.

On April 28, 2017 (the “ Effective Date ”), the Company consummated the merger contemplated by the Agreement and Plan of Merger, dated as of February 13, 2017 (the “ Merger Agreement ”), by and among the Company, Allergan Holdco US, Inc., a Delaware corporation (“ Allergan ”), and Blizzard Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Allergan (“ Merger Sub ”). Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Company (the “ Merger ”), with the Company surviving the Merger as a wholly-owned subsidiary of Allergan.

As a result of the consummation of the transactions contemplated by the Merger Agreement, the Company has terminated all offerings of the Company’s securities pursuant to the Registration Statements. Accordingly, pursuant to the undertaking contained in the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities being registered which remain unsold at the termination of the offering, the Company is filing these Post-Effective Amendments to deregister all of the securities registered and reserved for issuance under the Registration Statements which remained unissued as of the Effective Date.